METHODS: Our study included 35 POLE-mutated (POLEmut) EC cases and 395 non-POLEmut EEC cases.
RESULTS: Notably, we observed no presence of morules in POLEmut cases, while SD was identified in 20% of instances. Conversely, morules and SD were identified in 12.7% and 26.1% of non-POLEmut EC cases, respectively, with morules consistently linked to a POLE wild-type status. The nuclear β-catenin expression is typically absent in tumors with wild-type POLE (wt-POLE) status.
CONCLUSIONS: Our findings suggest that the presence of either morules or nuclear β-catenin expression in EEC could practically rule out the presence of POLE mutations. These morphologic and immunohistochemical features can be used as preliminary screening tools for POLE mutations, offering significant savings in time and resources and potentially enhancing clinical decision-making and patient management strategies. However, further validation in larger, multi-institutional studies is required to fully understand the implications of these findings on clinical practice.
方法:我们的研究包括35例POLE突变(POLEmut)EC病例和395例非POLEmutEEC病例。
结果:值得注意的是,我们在POLEmut病例中没有观察到桑树的存在,而SD在20%的情况下被识别。相反,在12.7%和26.1%的非POLEmutEC病例中发现了morules和SD,分别,moleules始终与POLE野生型状态相关。在具有野生型POLE(wt-POLE)状态的肿瘤中通常不存在核β-连环蛋白表达。
结论:我们的研究结果表明,在EEC中存在桑树或核β-catenin表达实际上可以排除POLE突变的存在。这些形态学和免疫组织化学特征可用作POLE突变的初步筛选工具。显著节省时间和资源,并有可能增强临床决策和患者管理策略。然而,在更大的范围内进一步验证,需要多机构研究才能充分了解这些发现对临床实践的影响.